A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

PURPOSE: Anti-KIR monoclonal antibodies (mAbs) can enhance the antitumor responses of natural killer (NK) cells. We evaluated the safety of the anti-KIR2D mAb lirilumab in patients with various cancers. EXPERIMENTAL DESIGN: Thirty-seven patients with hematological malignancies (n = 22) or solid tumo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Vey, Norbert, Karlin, Lionel, Sadot-Lebouvier, Sophie, Broussais, Florence, Berton-Rigaud, Dominique, Rey, Jérôme, Charbonnier, Aude, Marie, Delphine, André, Pascale, Paturel, Carine, Zerbib, Robert, Bennouna, Jaafar, Salles, Gilles, Gonçalves, Anthony
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915148/
https://ncbi.nlm.nih.gov/pubmed/29707140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24832
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi